Review
Chemistry, Medicinal
Ute Hennrich, Matthias Eder
Summary: Radiotracers targeting prostate-specific membrane antigen (PSMA) are commonly used for PET imaging of prostate cancer, with the recent approval of [Ga-68]Ga-PSMA-11 by the FDA in 2020. This radiopharmaceutical combines a peptidomimetic compound with the radionuclide Ga-68, allowing specific imaging of PSMA-positive tumor cells and potential applications in therapy planning and treatment response evaluation.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yining Wang, Zijun Chen, Yinjie Zhu, Haitao Zhao, Lianghua Li, Gang Huang, Wei Xue, Ruohua Chen, Jianjun Liu
Summary: The purpose of this study was to assess whether total-body [(68) Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. The results showed that total-body [(68) Ga]Ga-PSMA-11 PET/CT had better objective evaluation in terms of background noise, lesion prominence, liver SD, SNR, and lesion SUVmax compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT. Overall, total-body [(68) Ga]Ga-PSMA-11 PET/CT had a significantly higher detection rate for biochemical recurrent prostate cancer compared to conventional [(68) Ga]Ga-PSMA-11 PET/CT. Rating: 9/10.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Oncology
Ruizhe Huang, Yizhen Li, Haowen Wu, Boyi Liu, Xuanjun Zhang, Zhongxi Zhang
Summary: The aim of this study was to compare the diagnostic efficacy of Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI in patients with biochemically recurrent prostate cancer. A meta-analysis and systematic review were conducted, analyzing 37 studies involving 8409 patients. The results showed that Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI had similar detection rates for biochemically recurrent prostate cancer. However, larger prospective studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ruohua Chen, Yee Ling Ng, Xinlan Yang, Yinjie Zhu, Lianghua Li, Haitao Zhao, Yun Zhou, Gang Huang, Jianjun Liu
Summary: Total-body parametric imaging of [(68) Ga]Ga-PSMA-11 improved lesion contrast and detectability compared to SUV images, which may serve as an imaging biomarker and theranostic tool for precise diagnosis and treatment evaluation in prostate cancer patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
David A. Pattison, Maciej Debowski, Brook Gulhane, Evyn G. Arnfield, Anita M. Pelecanos, Peter L. Garcia, Melissa J. Latter, Charles Y. Lin, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas
Summary: This study aimed to compare the concordance of [F-18]PSMA-1007 and [(68)Ga]Ga-PSMA-11 in TNM diagnosis and tracer uptake. The results showed differences in tracer uptake in most physiological sites, but high consistency in overall AJCC prognostic stage.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaomei Gao, Yongxiang Tang, Minfeng Chen, Jian Li, Hongling Yin, Yu Gan, Xiongbin Zu, Yi Cai, Shuo Hu
Summary: This study compared [Ga-68]Ga-RM26 PET/CT and [Ga-68]Ga-PSMA-617 PET/CT for diagnosing prostate cancer, and found that [Ga-68]Ga-PSMA-617 PET/CT had superior accuracy in detecting clinically significant PCa, while [Ga-68]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuheng Liu, Lianghua Li, Yanyu Qin, Zijun Chen, Haitao Zhao, Xinlu Wang, Ruohua Chen
Summary: The objective of this study was to compare the diagnostic performance and image quality of total-body PET/CT imaging using half-dose of [(68) Ga]Ga-PSMA radiotracer to conventional PET/CT imaging using full dose of [(68) Ga]Ga-PSMA. The results showed that total-body PET/CT with half-dose of [(68) Ga]Ga-PSMA yielded comparable image quality and diagnostic performance to conventional PET/CT, while reducing radiation exposure for the subjects.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kaan Akcay, Ali Kibar, Onur Erdem Sahin, Muhammet Demirbilek, Gamze Beydagi, Sertac Asa, Fuad Aghazada, Turkay Toklu, Nalan Alan Selcuk, Bulent Onal, Levent Kabasakal
Summary: The study retrospectively reviewed 147 patient records and found that [(68) Ga]Ga-PSMA-11 PET/CT imaging has potential value in diagnosing clinically significant prostate cancer. PRIMARY scoring was more reliable than PIRADS scoring in diagnosing significant prostate cancer.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhilong Yi, Siqi Hu, Xiaofeng Lin, Qiong Zou, MinHong Zou, Zhanlei Zhang, Lei Xu, Ningyi Jiang, Yong Zhang
Summary: The study investigated the use of machine learning-based radiomics models derived from (68) Ga-PSMA PET images to predict invisible intraprostatic lesions. Results showed that these models could accurately predict such lesions and outperformed PSA density in diagnostic performance.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Medicine, General & Internal
Jolanta Kunikowska, Kacper Pelka, Omar Tayara, Leszek Krolicki
Summary: This study evaluated the usefulness of delayed phase images in Ga-68-PSMA-11 PET/CT and found that this technique has an impact on treatment management in 16% of prostate cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Heying Duan, Lucia Baratto, Negin Hatami, Tie Liang, Craig S. Levin, Mohammad Mehdi Khalighi, Andrei Iagaru
Summary: The study evaluates the effect of different reduced PET acquisition times in patients with prostate cancer who underwent Ga-68-PSMA-11 or (68)GaRM2 PET/MRI. Results suggest that routine 3-minute acquisitions provide similar results to 4-minute acquisitions, while 2-minute acquisitions provide acceptable performance.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wojciech Cytawa, Stefan Kircher, Hubert Kuebler, Rudolf A. Werner, Simon Weber, Philipp Hartrampf, Tomasz Bandurski, Piotr Lass, Wojciech Polom, Marcin Matuszewski, Hans-Juergen Wester, Constantin Lapa, Andreas Rosenwald, Anna Katharina Seitz, Andreas K. Buck
Summary: The purpose of this study was to validate the expression of primary tumor PSMA in prostate cancer patients using [Ga-68]Ga-PSMA PET/CT imaging. The results showed that among PSMA-positive patients, about one-third had lymph node metastases, which were associated with PSMA expression and tumor volume. In contrast, only 1 out of 7 PET-negative patients had lymph node involvement. These results suggest that PSMA-positive prostate cancer may have a higher risk of aggressiveness and distant metastasis.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jake Kendrick, Roslyn J. Francis, Ghulam Mubashar Hassan, Pejman Rowshanfarzad, Jeremy S. L. Ong, Michael McCarthy, Sweeka Alexander, Martin A. Ebert
Summary: This study aimed to validate the RECIP 1.0 criteria in biochemically recurrent prostate cancer patients and determine if this classification could be fully automated using an AI model. The study found that RECIP 1.0 was prognostic and could be used to assess disease progression in PCa patients with less advanced disease.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Giacomo Feliciani, Monica Celli, Fabio Ferroni, Enrico Menghi, Irene Azzali, Paola Caroli, Federica Matteucci, Domenico Barone, Giovanni Paganelli, Anna Sarnelli
Summary: Radiomics analysis is applied to MRI-ADC and [68Ga]Ga-PSMA-11 PET maps to assess tumor characteristics and predict ISUP grades. The models based on MRI-ADC and [68Ga]Ga-PSMA-11 PET imaging features show promising results in predicting low ISUP grade patients and reducing overdiagnosis of indolent, early-stage PCa.
Article
Oncology
Fuquan Deng, Xiaoyuan Li, Fengjiao Yang, Hongwei Sun, Jianmin Yuan, Qiang He, Weifeng Xu, Yongfeng Yang, Dong Liang, Xin Liu, Greta S. P. Mok, Hairong Zheng, Zhanli Hu
Summary: This study used deep learning methods to perform low-dose image restoration on PSMA PET/MRI and found that synthesizing full-dose PET images based on MRI priors using 50% dose PET images did not affect the clinical diagnosis of prostate cancer. Prostate cancer patients can undergo 68Ga-PSMA prostate PET/MRI scans with radiation doses reduced by up to 50% through the use of deep learning methods to synthesize FDPET images.
FRONTIERS IN ONCOLOGY
(2022)
